Structure-guided vaccination elicits broadly neutralizing antibodies targeting the HIV-1 silent face
Carter, J. J.; Palacio, M. B.; Berlaga, M.; Olajide, O.; Noh, J. J.; Lee, Y. E.; Ramos, I.; Eso, M. R.; Phung, J.; Chen, T.; Meka, S.; Garay, M. G.; Seaman, M. S.; Escolano, A.; Barnes, C. O.
Show abstract
An effective HIV-1 vaccine will likely require broadly neutralizing antibodies (bnAbs) targeting multiple complementary epitopes on the Envelope (Env) glycoprotein. Donor-derived bnAbs targeting the conserved silent face (SF) epitope complement established bnAb classes, but the maturation pathways underlying SF bnAb development and their inducibility via vaccination remain poorly understood. Here, we elicit SF-like bnAbs by vaccination and define pathways by which these responses can be guided toward breadth. Structural analysis of the donor-derived bnAb SF10 revealed that broad neutralization depends on a minimal set of heavy chain mutations despite extensive overall somatic hypermutation. We leveraged these insights to engineer Env immunogens that engage an SF10 precursor and selectively favor breadth-associated mutations during sequential immunization in a new immunoglobulin knock-in mouse model. Vaccination reproducibly elicited heterologous neutralizing serum responses and monoclonal antibodies that acquired key SF-like improbable mutations and broad neutralizing activity. Notably, elicited antibodies combined features of distinct human SF bnAbs, demonstrating that vaccination can access alternative mutational solutions rather than precisely recapitulating a donor-derived maturation pathway. These findings establish the silent face as a tractable vaccine target and expand the bnAb specificities available for multi-epitope HIV-1 vaccine strategies.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques 97%
- HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy 95%
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease 95%
Similar papers in this journal
- HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design 96%
- Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3 96%
- Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad Neuraminidase Inhibition by Human Antibodies 95%
Similar papers in this journal
- Deep Mining of the Human Antibody Repertoire Identifies Frequent and Immunogenetically Diverse CDRH3 Topologies Targetable by Vaccination 96%
- Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial 95%
- Distinct modes of evolution drive HIV escape from two broadly neutralizing antibodies. 95%
Similar papers in this journal
- Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination 95%
- Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma 95%
- Broadly neutralizing antibodies target the coronavirus fusion peptide 95%
Similar papers in this journal
- Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2 95%
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals 95%
- A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.